Protein aggregation in the aging retina

Journal of Neuropathology and Experimental Neurology

Volumn 70, Issue 1, 2011, Pages 63-68

  Leger, François ^a   Fernagut, Pierre Olivier ^b   Canron, Marie Hélène ^b   Léoni, Sandy ^a   Vital, Claude ^b   Tison, François ^a,b   Bezard, Erwan ^b   Vital, Anne ^a,b  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b INSTITUT DES MALADIES NEURODÉGÉNÉRATIVES   (France)

Author keywords

Aging; Protein aggregation; Retina; Tau protein; Ubiquitin; Synuclein; A4 Amyloid

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; TAU PROTEIN; UBIQUITIN;

ADULT; AGED; AGING; ARTICLE; BRUCH MEMBRANE; CELL INCLUSION; CLINICAL ARTICLE; CYTOPLASM; DRUSEN; ENUCLEATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNE COMPLEX DEPOSITION; IMMUNOHISTOCHEMISTRY; MALE; PHOTORECEPTOR CELL; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN LOCALIZATION; RETINA; RETINA BIPOLAR GANGLION CELL; RETINA GANGLION CELL; RETINA NEUROEPITHELIAL LAYER;

EID: 78650679174     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/NEN.0b013e31820376cc     Document Type: Article

References (18)

1. Hanger DP, Anderton BH, Noble W. Tau phosphorylation: The therapeutic challenge for neurodegenerative disease. Trends Mol Med 2009; 15:112-9
2. Duda JE, Lee VM-Y, Trojanowski JQ. Neuropathology of synuclein aggregates: New insights into mechanisms of neurodegenerative diseases. J Neurosci Res 2000;61:121-7
3. Crouch PJ, Harding S-ME, White AR, et al. Mechanisms of AA mediated neurodegeneration in Alzheimer's disease. Int J Biochem Cell Biol 2008; 40:181-98
4. Shringarpure R, Davies KJA. Protein turnover by the proteasome in aging and disease. Free Radic Biol Med 2002;32:1084-89
5. Bence NF, Sampat RM, Kopito RR. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 2001;292:1552-55
6. Sherman MY, Goldberg AL. Cellular defenses against unfolded proteins: A cell biologist thinks about neurodegenerative diseases. Neuron 2001; 29:15-32
7. Löffler KU, Edward DP, Tso MOM. Immunoreactivity against tau, amyloid precursor protein and beta-amyloid in the human retina. Invest Ophthalmol Vis Sci 1995;36:24-31
8. Chapple JP, Grayson C, Hardcastle AJ, et al. Unfolding retinal dystrophies: A role for molecular chaperones? Trends Mol Med 2001;7:414-21
9. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med 2008;358:2606-17
10. Surgucheva I, Ninkina N, Buchman VL, et al. Protein aggregation in retinal cells and approaches to cell protection. Cell Mol Neurobiol 2005; 25:1051-66
11. Saliba RS, Munro PMG, Luthert PJ, et al. The cellular fate of mutant rhodopsin: Quality control, degradation and aggresome formation. J Cell Sci 2002;115:2907-18
12. Chapple JP, Cheetham ME. The chaperone environment at the cyto-plasmic face of the endoplasmic reticulum can modulate rhodopsin processing and inclusion formation. J Biol Chem 2003;278:19087-94
13. Klenotic PA, Munier FL, Marmorstein LY, et al. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a binding partner of epithelial growth factorYcontaining fibulin-like extracellular matrix protein 1 (EFEMP1). J Biol Chem 2004;279:30469-73
14. Surguchov A, McMahan B, Masliah E, et al. Synucleins in ocular tissues. J Neurosci Res 2001;65:68-77
15. Andorfer C, Acker CM, Kress Y, et al. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci 2005;25:5446-54
16. Goldberg MS, Lansbury PT. Is there a cause-and-effect relationship between >-synuclein fibrillization and Parkinson's disease? Nat Cell Biol 2000;2:E115-19
17. Uversky VN. Neuropathology, biochemistry, and biophysics of >-synuclein aggregation. J Neurochem 2007;103:17-37
18. Lee H, Zhu X, Takeda A, et al. Emerging evidence for the neuro-protective role of >-synuclein. Exp Neurol 2006;200:1-7